Oncolytic viruses (OVs), without harming normal tissues, selectively infect and replicate within tumor cells, to release immune molecules and tumor antigens, achieving immune-mediated destruction of tumors and making them one of the most promising immunotherapies for cancer. Many clinical studies have demonstrated that OVs can provide clinical benefits for patients with different types of tumors, at various stages, including metastatic and previously untreatable cases. When OVs are used in combination with chemotherapy, radiotherapy, immunotherapy, and other treatments, they can synergistically enhance the therapeutic effects. The concept of oncolytic virotherapy (OVT) was proposed in the early 20th century. With advancements in genetic engineering, genetically modified viruses can further enhance the efficacy of cancer immunotherapy. In recent years, global research on OV treatment of malignant tumors has increased dramatically. This article comprehensively reviews the findings from relevant research and clinical trials, providing an overview of the development of OVT and its application in the clinical treatment of head and neck cancer. The aim is to offer insights for future clinical and fundamental research on OVT.
溶瘤病毒（Oncolytic viruses，OVs）在不损伤正常组织的前提下，选择性感染并在肿瘤细胞内复制，释放免疫分子和肿瘤抗原，实现免疫介导的肿瘤破坏，使其成为最具前景的癌症免疫疗法之一。多项临床研究表明，OVs能为不同类型、不同阶段（包括转移性和既往无法治疗的病例）的肿瘤患者带来临床获益。当OVs与化疗、放疗、免疫疗法等其他治疗手段联合应用时，可协同增强治疗效果。溶瘤病毒疗法（Oncolytic virotherapy，OVT）的概念早在20世纪初便被提出，随着基因工程技术的发展，经过基因改造的病毒能进一步提升癌症免疫治疗的疗效。近年来，全球关于OV治疗恶性肿瘤的研究大幅增加。本文综合相关研究及临床试验结果，概述OVT的发展历程及其在头颈癌临床治疗中的应用，以期为未来OVT的临床及基础研究提供参考。
Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer
肿瘤(癌症)患者之家